Tender and Contract Specialist with French
About the job
- A bachelor's degree or equivalent qualification is required.
- Fluency in French and a good working knowledge of English are required.
- A minimum of two years of professional experience is required, ideally including support for tender, contract, project coordination, or administrative processes.
- Proficiency in Microsoft Office applications, particularly Excel, is required.
- Strong organisational skills, attention to detail, and the ability to manage multiple priorities while meeting deadlines are required.
- An English version of the CV must be submitted.
- Monitor tender opportunities across assigned regions and identify relevant calls for tender.
- Inform Sales Representatives of new tender opportunities and follow up on required actions.
- Review tender documentation, terms, and conditions to ensure compliance with internal policies and applicable regulations.
- Prepare and submit tender documentation accurately and within established deadlines.
- Maintain tender-related documentation, including contracts, agreements, amendments, and supporting documents.
- Ensure proper classification, distribution, maintenance, and archiving of tender and contract documentation.
- Maintain accurate records in Salesforce and support the resolution of day-to-day contract and tender-related issues.
- Experience within biotechnology, life sciences, diagnostics, healthcare, medical devices, or pharmaceutical industries is advantageous.
- Legal or contract administration experience is a plus.
- Additional language skills, particularly German, are advantageous.
- Salesforce or CRM experience is preferred.
About the company
QIAGEN provides molecular testing solutions for DNA, RNA, and proteins used by researchers and clinicians in life sciences and diagnostics. It offers an end-to-end portfolio spanning sample technologies, assay technologies, and bioinformatics software to guide workflows from sample to data interpretation. Notable products include QIAseq UPXome RNA Library Kits, the QIAstat Dx Viral Vesicular Panel, and the QIAstat Dx Analyzer, a scalable digital PCR system. Its goal is to help users obtain fast, reliable molecular insights by offering an integrated mix of hardware, reagents, and software that support research and patient care.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
Venlo, Netherlands
Founded
1984
Get referred to QIAGEN
See people who can refer or advise you
Simplify's Take
What believers are saying
- On September 28, 2026, FDA cleared QIAstat-Dx bloodstream infection panels covering 33 targets.
- On September 24, 2026, QIAGEN launched QIAmini, its third sample-prep system of 2026.
- Q2 2026 sales held at $535 million, and adjusted EPS beat guidance at $0.62.
What critics are saying
- U.S. immigration testing demand dragged QuantiFERON growth to 1% in Q2 2026.
- Instrument sales fell in Q2 2026, signaling weak lab capital spending across markets.
- The strategic review and private-equity sale talks stall, trapping QIAGEN in slow-growth limbo.
What makes QIAGEN unique
- QIAGEN's 5,200-plus QIAstat-Dx placements lock labs into recurring consumables revenue.
- Its integrated sample-to-result platforms bundle extraction, PCR, and analytics in one workflow.
- QIAGEN spans research and diagnostics, with FDA-cleared menus across respiratory, GI, and bloodstream infections.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Bonus/Commission
Local benefits
Referral Program
Volunteer Day
Hybrid Work Options
Employee Assistance Program
Growth & Insights and Company News
6 month growth
0%1 year growth
0%2 year growth
0%QIAGEN adds evidence-traceable AI tools to bioinformatics and drug discovery workflows. IPA Investigator introduces natural-language biological analysis while the QIAGEN Discovery Platform extends AI into automated drug discovery workflows. QIAGEN has introduced new AI capabilities for biological and genomic data analysis and drug discovery workflows. QIAGEN has introduced new artificial intelligence capabilities across QIAGEN Digital Insights to help researchers analyze biological and genomic data while keeping the scientific evidence behind results visible. The launch includes IPA Investigator for QIAGEN Ingenuity Pathway Analysis and the new QIAGEN Discovery Platform for drug discovery workflows. QIAGEN says the additions build on more than 25 years of biomedical knowledge and bioinformatics tools used by around 150,000 users. (PRESS RELEASE) VENLO, Netherlands, 7-Oct-2026 - /EuropaWire/ - QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) has announced new artificial intelligence (AI) capabilities designed to help researchers analyze complex biological and genomic data faster while keeping the scientific evidence behind the results visible. The expansion includes IPA Investigator, a new AI research companion for QIAGEN Ingenuity Pathway Analysis (IPA), and the new QIAGEN Discovery Platform, which extends these capabilities into automated drug discovery workflows. The new offerings build on more than 25 years of biomedical knowledge from QIAGEN Digital Insights (QDI), whose bioinformatics solutions are used by around 150,000 users. The global market for AI in bioinformatics is projected to more than double from about $12 billion in 2026 to more than $25 billion by 2031, according to Mordor Intelligence. As researchers increasingly use AI to analyze growing volumes of biological and genomic data, QIAGEN said speed alone is not enough. The company combines AI with expert-reviewed biological, genomic and clinical information so scientists can examine the evidence behind the results. "AI can deliver an answer in seconds, but in science, speed without evidence can create false confidence," said Dominic John, Vice President and Head of QIAGEN Digital Insights. "Our approach is to combine the speed of AI with expert-curated biomedical knowledge and traceable scientific evidence so researchers can examine the evidence behind the results and evaluate them for themselves." IPA Investigator allows scientists to ask questions about their data in natural language. It can identify relevant biological relationships, recommend analyses and carry them out within IPA. Researchers can then connect their own experimental data with existing biological knowledge to better understand disease, identify potential drug targets and decide what to investigate next. At the University of Bergen in Norway, researchers tested IPA Investigator using complex datasets that deliberately introduced misleading sample comparisons. "We deliberately introduced misleading comparisons to see how IPA Investigator would respond. It identified the problem, cautioned us against overinterpreting the results and suggested a better experimental design," said Dr. Simona Chera, Professor at the University of Bergen. QIAGEN is also introducing the QIAGEN Discovery Platform, which enables the integration of AI with QIAGEN's biomedical knowledge base and molecular data to support drug discovery. The platform is designed to help researchers identify potential drug targets and biomarkers, generate research hypotheses and automate parts of the discovery process. The launches are part of a broader rollout of AI across QIAGEN Digital Insights, including AI-powered translation in QIAGEN Clinical Insight (QCI) Interpret and machine learning combined with expert-reviewed information in Franklin by QIAGEN. About QIAGEN. QIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the interpretation of complex data to deliver actionable insights. Automation solutions integrate these steps into streamlined, cost-effective workflows. QIAGEN serves more than 500,000 customers worldwide in the Life Sciences (academia, pharmaceutical R&D and industrial applications such as forensics) and Molecular Diagnostics (clinical healthcare). As of June 30, 2026, QIAGEN employed about 5,500 people across more than 35 locations. For more information, visit http://www.qiagen.com. Forward-Looking statement. Certain statements in this press release may constitute forward-looking statements within the meaning of the U.S. federal securities laws. These statements include, among others, statements regarding QIAGEN's products, product development and launches, regulatory approvals, market opportunities and future business performance. Forward-looking statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially. These risks include, among others, the development and commercial success of new products, regulatory approvals, competition, changes in customer demand and funding, economic and market conditions, supply chain disruptions, cybersecurity incidents, litigation and other risks described under "Risk Factors" in QIAGEN's most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. QIAGEN undertakes no obligation to update any forward-looking statement except as required by law. IR contacts. Daniel Wendorff Vice President Head of Investor Relations Mobile: +49 152 01811322 [email protected] Dr. Domenica Martorana Associate Director Global Investor Relations Mobile: +49 152 018 11244 [email protected] Alexandra Koenig Investor Relations Coordinator Mobile: +49 152 018 11709 [email protected] Press contacts. John Gilardi Vice President Head of Corporate Communications Global Germany: +49 2103 29 11711 Mobile: +49 152 018 11711 [email protected] Lisa Specht Manager Public Relations Corporate Communications Germany: +49-2103-29-14181 Mobile: +49-152-018-11381 [email protected] Jana Radoi Corporate Communications Coordinator Global Mobile: +49 152 018 11670 [email protected] Heeyoung Lee Asia-Pacific region topics South Korea: +82 226265788 Mobile: +82 01093389650 [email protected] Natalia Silo Latin America region topics Mobile: +55 11 98702 0137 [email protected]
QIAGEN has launched new AI-powered bioinformatics tools to help researchers analyse biological and genomic data while maintaining visibility of scientific evidence. The expansion includes IPA Investigator, an AI research companion that allows scientists to ask questions in natural language, and the QIAGEN Discovery Platform for drug discovery workflows. The tools build on over 25 years of biomedical knowledge from QIAGEN Digital Insights, used by around 150,000 researchers. The global AI bioinformatics market is projected to grow from $12 billion in 2026 to over $25 billion by 2031, according to Mordor Intelligence. IPA Investigator can identify biological relationships, recommend analyses, and help researchers understand disease and identify potential drug targets. The QIAGEN Discovery Platform enables integration of AI with molecular data to support drug discovery, helping identify drug targets and biomarkers whilst automating parts of the discovery process.
QIAGEN N.V. Expands ai-powered bioinformatics with IPA Investigator and QIAGEN Discovery Platform. Published on 10/06/2026 at 04:05 pm EDT S&P Capital IQ QIAGEN N.V. announced new artificial intelligence (AI) capabilities to help researchers analyze complex biological and genomic data faster while keeping the scientific evidence behind the results visible. The expansion includes IPA Investigator, a new AI research companion for QIAGEN Ingenuity Pathway Analysis (IPA), and the new QIAGEN Discovery Platform, which extends these capabilities into automated drug discovery workflows. As researchers increasingly use AI to analyze growing volumes of biological and genomic data, speed alone is not enough. QIAGEN combines AI with expert-reviewed biological, genomic and clinical information so scientists can examine the evidence behind the results. IPA Investigator allows scientists to ask questions about their data in natural language. It can identify relevant biological relationships, recommend analyses and carry them out within IPA. Researchers can then connect their own experimental data with existing biological knowledge to better understand disease, identify potential drug targets and decide what to investigate next. At the University of Bergen in Norway, researchers tested IPA Investigator using complex datasets that deliberately introduced misleading sample comparisons. QIAGEN is also introducing the QIAGEN Discovery Platform, which enables the integration of AI with QIAGEN?s biomedical knowledge base and molecular data to support drug discovery. The platform is designed to help researchers identify potential drug targets and biomarkers, generate research hypotheses and automate parts of the discovery process. The launches are part of a broader rollout of AI across QIAGEN Digital Insights, including AI-powered translation in QIAGEN Clinical Insight (QCI) Interpret and machine learning combined with expert-reviewed information in Franklin by QIAGEN. (C) S&P Capital IQ - 2026
QIAGEN completes U.S. QIAstat-Dx bloodstream infection portfolio with FDA clearance of new bacteria detection panel. Key Takeaway: QIAGEN N.V. has announced the FDA clearance of a new bacteria detection panel for its QIAstat-Dx bloodstream infection portfolio. This new panel allows U.S. laboratories to detect gram-negative bacteria and antibiotic resistance markers in approximately one hour. It complements an earlier FDA-cleared panel for gram-positive bacteria and fungi, enhancing the company's diagnostic capabilities. Market sentiment analysis. Positive factors. * FDA clearance expands QIAGEN's product offerings. * New panel detects bacteria and antibiotic resistance quickly. * Enhances capabilities for U.S. laboratories. GERMANTOWN, Md. & VENLO, Netherlands-(BUSINESS WIRE)- $QGEN #QIAGEN-QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that U.S. laboratories now have access to the complete QIAstat-Dx bloodstream infection portfolio following clearance of a new panel by the U.S. Food and Drug Administration (FDA). The new panel detects gram-negative bacteria and antibiotic resistance markers in about one hour, complementing the recently FDA-cleared QIAstat-Dx panel for gram-positive bacteria and fungi. Frequently asked questions. What is the new panel from QIAGEN designed to detect? The new panel detects gram-negative bacteria and antibiotic resistance markers. How quickly can the new QIAstat-Dx panel provide results? The new panel can provide results in about one hour. What does the new panel complement? It complements the previously FDA-cleared panel for gram-positive bacteria and fungi. Who cleared the new bacteria detection panel? The U.S. Food and Drug Administration (FDA) cleared the new panel.
Warren Wise decodes Qiagen's DNA. EQS-News: CPT GmbH / Key word(s): Research Update/Annual Report Warren Wise decodes Qiagen's DNA 25.09.2026 / 18:15 CET/CEST The issuer is solely responsible for the content of this announcement. WARREN WISE * Recurring revenues, strong cash flow and hardly any debt - does this mean Qiagen's future is secure? * Qiagen aims to grow almost twice as fast as the market in many of its business areas, while cutting back on R&D - can this work? * The podcast "Warrens Watchlist" analyzes the largest companies in the DAX and MDAX. Now available wherever you get your podcasts and at warren-wise.com. Wiesbaden, September 25, 2026 - Whether it is a blood test in a clinic, cancer research or a DNA trace in a forensic laboratory: before genetic material can be analyzed, it first has to be extracted from the sample. Many of the kits used for this purpose come from Qiagen N.V. (ISIN: NL0015002SN0). In the latest episode of the podcast "Warrens Watchlist," Warren Wise examines the company's own equity story like a forensic investigator. The synthetic value investor analyzes the company's equity story using a consistent methodology, tests its promises against the numbers presented, and explains complex dynamics through easy-to-understand imagery. Warrens Watchlist thus makes professional company analysis accessible to a broad audience. Strong business, question marks over R&D The initial findings are clear. Qiagen's business model is built on reliability: once a device is installed in a laboratory and approved for the tests performed there, customers continue ordering the corresponding consumables for years. Around 90 percent of the company's more than USD 2 billion in revenue is recurring. After investing in its own business, Qiagen generated around USD 450 million in free cash flow in fiscal 2025, more than its reported net income. Net financial debt was below one year's EBITDA at year-end, and for the first time in the company's history, shareholders received a dividend. "The evidence is solid when it comes to the business. When it comes to innovation, the evidence is thinner," Warren Wise summarizes. Qiagen has set itself ambitious targets: five product areas, including the QuantiFERON tuberculosis blood test and the QIAstat-Dx rapid testing system, are expected to increase their combined revenue from around USD 1.5 billion to around USD 2 billion by 2028, growing almost twice as fast as the market. At the same time, however, the share of employees working in research and development has recently declined, R&D spending as a percentage of revenue has fallen, and the Supervisory Board has dissolved its Science Committee. Any one of these developments would hardly be noteworthy on its own. Taken together, Warren Wise sees a pattern that warrants monitoring. The nearly fourfold increase in operating profit also looks different on closer inspection: the previous year was weighed down by almost USD 300 million in exceptional charges related to the discontinuation of the NeuMoDx diagnostic system. On an adjusted basis, the increase amounts to just over USD 50 million. It also remains unclear how much revenue the acquisitions of Parse Biosciences and Genoox contribute. Qiagen does not disclose the figure, even though the company's total goodwill now accounts for almost 70 percent of equity. Qiagen does not report a return on capital either. Warren Wise calculated the figure itself and arrives at a comparatively strong value of around 11 percent. The analysis concludes with a score of 4 out of 5 in the Warren Wise Report. This reflects an overall convincing equity story, albeit with little room to slip. Since September 1, 2026, Jonathan Pratt has been at the helm of the company, taking over amid a strategic review of the business. According to media reports, Qiagen is also up for sale, with several major financial investors reportedly having already expressed interest. Against this backdrop, what would Warren Wise ask Qiagen's new CEO? Warren Wise discusses these and other questions in the new episode together with Cori Capital, the AI-powered voice of retail investors. Be wise, when others go crazy! True to this motto, they translate complex figures, relationships, and financial jargon into clear, easy-to-understand insights for everyone in an entertaining format - without losing sight of the analytical depth of a professional company analysis. Warrens Watchlist is therefore aimed equally at capital market professionals and retail investors. About Warren Wise Warren Wise is an AI technology that analyzes and evaluates equity stories from the perspective of a long-term investor. Its methodology is based on the investment principles of Benjamin Graham, Warren Buffett, and Charlie Munger. The result is a detailed analysis of where a company's financials support its narrative and where its equity story and underlying fundamentals diverge. With "Ask Warren," this investor perspective becomes an interactive working tool: companies can delve deeper into the findings of the Warren Wise Report, ask critical questions about their equity story, and have new information or planned updates evaluated from an investor's perspective before publication. Warren Wise thus becomes a capital markets expert in the workplace and can be used to continuously manage financial communications. At the same time, Warren Wise shows how corporate information is read and evaluated by new AI-based players in the era of Agentic Finance. The 2026 Warren Wise Report, featuring an analysis of 40 companies from the DAX and MDAX, is available online free of charge here. Follow Warrens Watchlist: #AgenticAI #AgenticFinance #EquityResearch #InvestorRelations #Qiagen #ValueInvesting #WarrensWatchlist Press Contact Michael Diegelmann · +49 61120585512 · [email protected] Web: warren-wise.com Note: This publication is intended solely for general informational purposes and does not constitute investment advice, research within the meaning of applicable regulatory requirements, or a recommendation to buy, hold, or sell financial instruments. Scores and assessments are model-based, point-in-time evaluations according to the published methodology and may contain errors. Warren Wise is a fictional, synthetic character. 25.09.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this announcement. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. View original content: EQS News 2405808 25.09.2026 CET/CEST